Aventis Behring LLC
Division of CSL Ltd.
Latest From Aventis Behring LLC
The finer points of when exactly the US government can collect from a device company for selling it a bill of goods are under reconsideration, even as the fast pace of False Claims Act suits continues, attorneys with law firm Gibson Dunn concluded during a series of recent webinars.
CoGenesys has licensed rights to albumin fusion proteins that improve the bioavailability of proteins better than other methods such as PEGylation, its founders believe. The start-up's pipeline presently contains a version of BNP for treating heart failure.
Aventis SA's oncology franchise is anchored by the blockbuster Taxotere. Sales of the drug comprise more than 8% of Aventis's core pharma business, and are currently growing more than 25% worldwide and in the US. Yet until recently, the firm had few other products with which to leverage its commercial infrastructure in oncology. It is therefore teaming up with ImmunoGen Inc. to create antibody-based oncology therapeutics using drug targets provided by both companies.
With Human Genome Sciences freed from obligations to share its genomics data exclusively with the 6-company human gene therapeutic consortium, HGS is set to look for its own new product-oriented alliances. But the 8-year-old company and its consortium have yielded only four compounds in clinical trials. HGS CEO William Haseltine says that the company can leverage its tremendous assets to strike potentially rich deals. The key question is how many human therapeutic proteins remain to be uncovered.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Wound Healing & Tissue Repair
- Centeon LLC
- North America
- Parent & Subsidiaries
- CSL Ltd.
- Senior Management
Ruedi E Waeger, PhD, CEO
Henri F Mura, Chief Mktg. Officer
James Fickenscher, Dir., Bus. Dev.
Ulrich Delvos, MD, PhD, SVP, R&D & CSO
- Contact Info
Aventis Behring LLC
Phone: (610) 878-4000
1020 First Ave.
King of Prussia, PA 19406-1310